

RECEIVED
CENTRAL FAX CENTER

OCT 05 2006

2

Docket No. GJE-7647
Serial No. 10/575,998In the Claims

This listing of claims will replace all prior versions and listings of claims in this application.

1-24 (canceled).

25 (currently amended). A (+)- or ~~(-)-erythro-mefloquine~~ (-)-erythro-mefloquine hydrochloride having one or more of the following characteristics:

a) (+)- or ~~(-)-erythro-mefloquine~~ (-)-erythro-mefloquine hydrochloride in a crystalline form which exhibits a characteristic X-ray powder diffraction pattern with peaks expressed in d-values (Å) of: 5.95 (s) and 4.02 (w);

b) (+)- or (-)-erythro-Mefloquine hydrochloride comprising particles having a size distribution of 30 to 150 µm, in a crystalline form which exhibits a characteristic X-ray powder diffraction pattern with peaks expressed in d-values (Å) of:

22.3 (vw), 11.2 (vs), 9.0 (w), 8.2 (vw), 7.4 (vw), 6.8 (vw), 6.5 (vw), 6.3 (vw), 6.1 (vw), 6.0 (vw), 5.94 (vw), 5.61 (m), 5.42 (w), 4.89 (vw), 4.74 (w), 4.54 (w), 4.12 (s), 4.02 (w), 3.81 (vvs), 3.74 (vs), 3.70 (vw), 3.64 (w), 3.55 (w), 3.47, (vw), 3.40 (vw), 3.34 (vw), 3.31 (vw), 3.26 (vs), 3.11 (vw), 3.04 (w), 2.97 (vw), 2.94 (vw), 2.81 (vw), 2.75 (m), 2.71 (w), 2.69 (w), 2.64 (w), 2.62 (w), 2.54 (vw), 2.46 (vw), 2.43 (vw), 2.40 (vw), 2.35 (vw), 2.30 (vw), 2.27 (vw), 2.24 (vw), 2.22 (vw), 2.17 (vs), 2.08 (vw), 2.06 (vw), 2.04 (vw), 1.94 (w), 1.91 (vw) and 1.88 (vw);

c) (+)- or (-)-erythro-mefloquine hydrochloride comprising particles having a size distribution of 1 to 10 µm, in a crystalline form which exhibits a characteristic X-ray powder diffraction pattern with peaks expressed in d-values (Å) of:

11.2 (m), 9.0 (w), 8.30 (vw), 7.4 (vw), 6.8 (vw), 6.3 (w), 6.1 (vw), 6.0 (vw), 5.95 (vw), 5.59 (w), 5.42 (w), 4.91 (vw), 4.74 (w), 4.55 (vw), 4.16 (w), 4.12 (s), 4.03 (w), 3.82 (vvs), 3.75 (w), 3.71 (w), 3.64 (w), 3.55 (w), 3.47 (vw), 3.40 (vw), 3.33 (w), 3.26 (w), 3.11 (vw), 3.04 (vw), 2.94 (vw), 2.75 (w), 2.71 (vw), 2.69 (vw), 2.64 (w), 2.62 (vw), 2.54 (vw), 2.46 (vw), 2.43 (vw), 2.40

J:\GJE\7647\PTO\2-Prelamend.doc\la

(vw), 2.35 (vw), 2.30 (vw), 2.26 (vw), 2.22 (vw), 2.17 (w), 2.08 (vw), 2.06 (vw), 1.99 (vw), 1.91 (vw) and 1.89 (vw);

d) (+)- or (-)-*erythro*-mefloquine hydrochloride in a crystalline form which exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}), of:
1030.2 (w) and 85.4 (vs);

e) (+)- or (-)-*erythro*-mefloquine hydrochloride in a crystalline form which exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}), of:
2877 (m), 1601 (s), 1585 (s), 1363 (vs), 1028.2 (w), 320 (m) and 118 (vs);

f) (+)- or (-)-*erythro*-mefloquine hydrochloride which, as an acetone solvate, is in the form of a crystalline pseudo-polymorph which exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}) of:
1602 (s), 1585 (s), 1363 (vs), 322 (m) and 118 (vs);

g) (+)- or (-)-*erythro*-mefloquine hydrochloride which, as a tetrahydrofuran solvate, is in the form of a crystalline pseudo-polymorph which exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}), of:
1601 (s), 1585 (s), 1363 (vs), 323 (m) and 119 (vs);

h) (+)- or (-)-*erythro*-mefloquine hydrochloride which, as a methyl ethyl ketone solvate, exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}), of:
1600 (s), 1585 (s), 1363 (vs), 319 (m) and 118 (vs); and

i) (+)- or (-)-*erythro*-mefloquine hydrochloride, which is substantially in the form of thick columns, cuboids, cubes or cube-like particles.

26 (currently amended). The (+)- or ~~(-)-*erythro*-mefloquine~~ (-)-*erythro*-mefloquine hydrochloride, according to claim 25, in a crystalline form which exhibits a characteristic X-ray powder diffraction pattern with peaks expressed in d-values (\AA) of: 5.95 (s) and 4.02 (w).

27 (currently amended). The (+)- or (-)-~~erythro-mefloquine~~ (-)-erythro-mefloquine hydrochloride according to claim 26, wherein the pattern also has peaks, expressed in d-values (Å), of:

11.2 (vs), 9.0 (s), 7.4 (w), 6.8 (w), 6.3 (s), 6.1 (m), 6.0 (m), 5.95 (s), 5.58 (m), 5.42 (m), 4.91 (m), 4.87 (w), 4.47 (s), 4.55 (w), 4.16 (vs), 4.12 (s), 4.10 (s), 4.02 (w), 3.82 (vs), 3.77 (w), 3.74 (s), 3.71 (vs), 3.64 (m), 3.47 (w), 3.40 (w), 3.33 (w), 3.31 (m), 3.27 (w), 3.25 (w), 3.11 (m), 3.04 (m), 2.94 (m), 2.92 (w), 2.75 (w), 2.70 (m), 2.68 (w), 2.64 (m), 2.62 (m), 2.54 (w), 2.45 (w), 2.39 (w), 2.35 (w), 2.30 (w), 2.29 (w), 2.25 (w), 2.22 (w), 2.18 (w), 2.17 (w), 2.08 (w), 1.99 (m), 1.95 (w), 1.91 (w), and 1.88 (w).

28 (currently amended). The (+)- or (-)-*erythro*-mefloquine hydrochloride, according to claim 25, comprising particles having a size distribution of 30 to 150 µm, in a crystalline form which exhibits a characteristic X-ray powder diffraction pattern with peaks expressed in d-values (Å) of:

22.3 (vw), 11.2 (vs), 9.0 (w), 8.2 (vw), 7.4 (vw), 6.8 (vw), 6.5 (vw), 6.3 (vw), 6.1 (vw), 6.0 (vw), 5.94 (vw), 5.61 (m), 5.42 (w), 4.89 (vw), 4.74 (w), 4.54 (w), 4.12 (s), 4.02 (w), 3.81 (vvs), 3.74 (vs), 3.70 (vw), 3.64 (w), 3.55 (w), 3.47, (vw), 3.40 (vw), 3.34 (vw), 3.31 (vw), 3.26 (vs), 3.11 (vw), 3.04 (w), 2.97 (vw), 2.94 (vw), 2.81 (vw), 2.75 (m), 2.71 (w), 2.69 (w), 2.64 (w), 2.62 (w), 2.54 (vw), 2.46 (vw), 2.43 (vw), 2.40 (vw), 2.35 (vw), 2.30 (vw), 2.27 (vw), 2.24 (vw), 2.22 (vw), 2.17 (vs), 2.08 (vw), 2.06 (vw), 2.04 (vw), 1.94 (w), 1.91 (vw) and 1.88 (vw).

29 (previously presented). The (+)- or (-)-*erythro*-mefloquine hydrochloride, according to claim 25, comprising particles having a size distribution of 1 to 10 µm, in a crystalline form which exhibits a characteristic X-ray powder diffraction pattern with peaks expressed in d-values (Å) of:

11.2 (m), 9.0 (w), 8.30 (vw), 7.4 (vw), 6.8 (vw), 6.3 (w), 6.1 (vw), 6.0 (vw), 5.95 (vw), 5.59 (w), 5.42 (w), 4.91 (vw), 4.74 (w), 4.55 (vw), 4.16 (w), 4.12 (s), 4.03 (w), 3.82 (vvs), 3.75 (w), 3.71 (w), 3.64 (w), 3.55 (w), 3.47 (vw), 3.40 (vw), 3.33 (w), 3.26 (w), 3.11 (vw), 3.04 (vw), 2.94

(vw), 2.75 (w), 2.71 (vw), 2.69 (vw), 2.64 (w), 2.62 (vw), 2.54 (vw), 2.46 (vw), 2.43 (vw), 2.40 (vw), 2.35 (vw), 2.30 (vw), 2.26 (vw), 2.22 (vw), 2.17 (w), 2.08 (vw), 2.06 (vw), 1.99 (vw), 1.91 (vw) and 1.89 (vw).

30 (currently amended). The (+)- or ~~(-)-erythro-mefloquine~~ (-)-erythro-mefloquine hydrochloride according to claim 25, which exhibits a characteristic X-ray powder diffraction pattern as exhibited in any of Figures 1, 2 and 3.

31 (previously presented). The (+)- or (-)-erythro-mefloquine hydrochloride, according to claim 25, in a crystalline form which exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}), of:
1030.2 (w) and 85.4 (vs).

32 (previously presented). The (+)- or (-)-erythro-mefloquine hydrochloride according to claim 25, in a crystalline form which exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}), of:
2877 (m), 1601 (s), 1585 (s), 1363 (vs), 1028.2 (w), 320 (m) and 118 (vs).

33 (previously presented). The (+)- or (-)-erythro-mefloquine hydrochloride, according to claim 25 which, as an acetone solvate, is in the form of a crystalline pseudo-polymorph which exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}) of:
1602 (s), 1585 (s), 1363 (vs), 322 (m) and 118 (vs).

34 (previously presented). The (+)- or (-)-erythro-mefloquine hydrochloride, according to claim 25 which, as a tetrahydrofuran solvate, is in the form of a crystalline pseudo-polymorph which exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}), of:
1601 (s), 1585 (s), 1363 (vs), 323 (m) and 119 (vs).

6

Docket No. GJE-7647
Serial No. 10/575,998

35 (previously presented). The (+)- or (-)-*erythro*-mefloquine hydrochloride according to claim 25, which, as a methyl ethyl ketone solvate, exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}), of:

1600 (s), 1585 (s), 1363 (vs), 319 (m) and 118 (vs).

36 (currently amended). The (+)- or ~~(-)-*erythro*-mefloquine~~ (-)-*erythro*-mefloquine hydrochloride according to claims 25, which is substantially in the form of thick columns, cuboids, cubes or cube-like particles.

37 (previously presented). The (+)- or (-)-*erythro*-mefloquine hydrochloride according to claim 36, in crystalline form B or C.

38 (currently amended). A process for the preparation of a (+)- or ~~(-)-*erythro*-mefloquine~~ (-)-*erythro*-mefloquine hydrochloride having one or more of the following characteristics:

a) (+)- or ~~(-)-*erythro*-mefloquine~~ (-)-*erythro*-mefloquine hydrochloride in a crystalline form which exhibits a characteristic X-ray powder diffraction pattern with peaks expressed in d-values (\AA) of: 5.95 (s) and 4.02 (w);

b) (+)- or (-)-*erythro*-mefloquine hydrochloride comprising particles having a size distribution of 30 to 150 μm , in a crystalline form which exhibits a characteristic X-ray powder diffraction pattern with peaks expressed in d-values (\AA) of:

22.3 (vw), 11.2 (vs), 9.0 (w), 8.2 (vw), 7.4 (vw), 6.8 (vw), 6.5 (vw), 6.3 (vw), 6.1 (vw), 6.0 (vw), 5.94 (vw), 5.61 (m), 5.42 (w), 4.89 (vw), 4.74 (w), 4.54 (w), 4.12 (s), 4.02 (w), 3.81 (vvs), 3.74 (vs), 3.70 (vw), 3.64 (w), 3.55 (w), 3.47, (vw), 3.40 (vw), 3.34 (vw), 3.31 (vw), 3.26 (vs), 3.11 (vw), 3.04 (w), 2.97 (vw), 2.94 (vw), 2.81 (vw), 2.75 (m), 2.71 (w), 2.69 (w), 2.64 (w), 2.62 (w), 2.54 (vw), 2.46 (vw), 2.43 (vw), 2.40 (vw), 2.35 (vw), 2.30 (vw), 2.27 (vw), 2.24 (vw), 2.22 (vw), 2.17 (vs), 2.08 (vw), 2.06 (vw), 2.04 (vw), 1.94 (w), 1.91 (vw) and 1.88 (vw);

c) (+)- or (-)-*erythro*-mefloquine hydrochloride comprising particles having a size distribution of 1 to 10 μm , in a crystalline form which exhibits a characteristic X-ray powder diffraction pattern with peaks expressed in d-values (\AA) of:

11.2 (m), 9.0 (w), 8.30 (vw), 7.4 (vw), 6.8 (vw), 6.3 (w), 6.1 (vw), 6.0 (vw), 5.95 (vw), 5.59 (w), 5.42 (w), 4.91 (vw), 4.74 (w), 4.55 (vw), 4.16 (w), 4.12 (s), 4.03 (w), 3.82 (vvs), 3.75 (w), 3.71 (w), 3.64 (w), 3.55 (w), 3.47 (vw), 3.40 (vw), 3.33 (w), 3.26 (w), 3.11 (vw), 3.04 (vw), 2.94 (vw), 2.75 (w), 2.71 (vw), 2.69 (vw), 2.64 (w), 2.62 (vw), 2.54 (vw), 2.46 (vw), 2.43 (vw), 2.40 (vw), 2.35 (vw), 2.30 (vw), 2.26 (vw), 2.22 (vw), 2.17 (w), 2.08 (vw), 2.06 (vw), 1.99 (vw), 1.91 (vw) and 1.89 (vw); and

d) (+)- or (-)-*erythro*-mefloquine hydrochloride in a crystalline form which exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}), of:

1030.2 (w) and 85.4 (vs);

wherein said process comprises either:

i) dissolution of another solid form of (+)- or (-)-*erythro*-mefloquine hydrochloride at a temperature from 20°C to 100°C in a solvent, to form a concentrated solution, optionally seeding and cooling the solution to precipitate (+)- or (-)-*erythro*-mefloquine hydrochloride, stirring the suspension for a time sufficient to complete formation of the desired crystalline form, removing the solvent, and drying the solid residue, or

ii) dissolution of another solid form of (+)- or (-)-*erythro*-mefloquine hydrochloride at a temperature from 20°C to 100°C in a solvent, to form a concentrated solution, optionally seeding and adding a sufficient amount of a non-solvent to precipitate (+)- or (-)-*erythro*-mefloquine hydrochloride, stirring the suspension for a time sufficient to complete formation of the desired crystalline form, removing the solvent, and drying the solid residue.

39 (previously presented). A process for the preparation of a crystalline form of (+)- or (-)-*erythro*-mefloquine hydrochloride, comprising the steps of:

a) dissolving or suspending substantially water-free (+)- or (-)-*erythro*-mefloquine free base at a temperature from 10 to 80°C in ethanol,

- b) adding aqueous HCl and water at a concentration, such that the formed (+)- or (-)-*erythro*-mefloquine hydrochloride is insoluble,
- c) shaking or stirring the resultant suspension and optionally also cooling it, and
- d) isolating the precipitate and drying the solid residue.

40 (previously presented). The process, according to claim 39, comprising the steps of:

- a) dissolving or suspending substantially water-free (+)- or (-)-*erythro*-mefloquine free base at a temperature from 40 to 80°C in ethanol,
- b) maintaining the temperature and adding aqueous HCl to form (+)- or (-)-*erythro*-mefloquine hydrochloride under shaking or stirring,
- c) slowly decreasing the temperature continuously or continuously and stepwise down to about 10°C to 30°C,
- d) adding water at the decreased temperature to reduce solubility of (+)- or (-)-*erythro*-mefloquine hydrochloride,
- e) shaking/stirring at the decreased temperature, and
- f) isolating the precipitate and drying the solid residue.

41 (currently amended). The process according to claim 39, for the preparation of

a (+)- or (-)-~~*erythro*-mefloquine~~ (-)-*erythro*-mefloquine hydrochloride in the form of cubes or cube-like forms, having one or more of the following characteristics:

a) (+)- or (-)-~~*erythro*-mefloquine~~ (-)-*erythro*-mefloquine hydrochloride in a crystalline form which exhibits a characteristic X-ray powder diffraction pattern with peaks expressed in d-values (Å) of: 5.95 (s) and 4.02 (w);

b) (+)- or (-)-*erythro*-mefloquine hydrochloride comprising particles having a size distribution of 30 to 150 µm, in a crystalline form which exhibits a characteristic X-ray powder diffraction pattern with peaks expressed in d-values (Å) of:

22.3 (vw), 11.2 (vs), 9.0 (w), 8.2 (vw), 7.4 (vw), 6.8 (vw), 6.5 (vw), 6.3 (vw), 6.1 (vw), 6.0 (vw), 5.94 (vw), 5.61 (m), 5.42 (w), 4.89 (vw), 4.74 (w), 4.54 (w), 4.12 (s), 4.02 (w), 3.81 (vvs), 3.74

(vs), 3.70 (vw), 3.64 (w), 3.55 (w), 3.47, (vw), 3.40 (vw), 3.34 (vw), 3.31 (vw), 3.26 (vs), 3.11 (vw), 3.04 (w), 2.97 (vw), 2.94 (vw), 2.81 (vw), 2.75 (m), 2.71 (w), 2.69 (w), 2.64 (w), 2.62 (w), 2.54 (vw), 2.46 (vw), 2.43 (vw), 2.40 (vw), 2.35 (vw), 2.30 (vw), 2.27 (vw), 2.24 (vw), 2.22 (vw), 2.17 (vs), 2.08 (vw), 2.06 (vw), 2.04 (vw), 1.94 (w), 1.91 (vw) and 1.88 (vw);

c) (+)- or (-)-*erythro*-mefloquine hydrochloride comprising particles having a size distribution of 1 to 10 μm , in a crystalline form which exhibits a characteristic X-ray powder diffraction pattern with peaks expressed in d-values (\AA) of:

11.2 (m), 9.0 (w), 8.30 (vw), 7.4 (vw), 6.8 (vw), 6.3 (w), 6.1 (vw), 6.0 (vw), 5.95 (vw), 5.59 (w), 5.42 (w), 4.91 (vw), 4.74 (w), 4.55 (vw), 4.16 (w), 4.12 (s), 4.03 (w), 3.82 (vvs), 3.75 (w), 3.71 (w), 3.64 (w), 3.55 (w), 3.47 (vw), 3.40 (vw), 3.33 (w), 3.26 (w), 3.11 (vw), 3.04 (vw), 2.94 (vw), 2.75 (w), 2.71 (vw), 2.69 (vw), 2.64 (w), 2.62 (vw), 2.54 (vw), 2.46 (vw), 2.43 (vw), 2.40 (vw), 2.35 (vw), 2.30 (vw), 2.26 (vw), 2.22 (vw), 2.17 (w), 2.08 (vw), 2.06 (vw), 1.99 (vw), 1.91 (vw) and 1.89 (vw); and

d) (+)- or (-)-*erythro*-mefloquine hydrochloride in a crystalline form which exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}), of:

1030.2 (w) and 85.4 (vs);

wherein said process comprises the steps of:

- a) dissolving or suspending substantially water-free (+)- or (-)-*erythro*-mefloquine free base at a temperature from 65 to 80°C in absolute ethanol,
- b) maintaining the temperature and continuously adding within 5 to 20 minutes under shaking or stirring concentrated aqueous HCl such that the water content in the ethanol/water mixture is from 20 to 3 and preferably 15 to 5 volume percent, to form a solution of (+)- or (-)-*erythro*-mefloquine hydrochloride in ethanol/water,
- c) continuously decreasing the temperature at a rate of 0.2 to 1K/min down to about 20°C to 30°C, or continuously decreasing the temperature in a first step at a rate of 0.2 to 1K/min 5 to 20°C lower as in step a), adding 0.5 to 2.5 percent by weight, referred to the amount of (+)- or (-)-*erythro*-mefloquine hydrochloride, of crystal seeds of the mefloquine hydrochloride according to any of claims 1 to 6, in cubic or cube-like morphological form,

10

Docket No. GJE-7647
Serial No. 10/575,998

stirring 15 to 30 minutes, and then continuously decreasing the temperature at a rate of 0.1 to 1K/min down to about 20°C to 30°C,

- d) adding water at the decreased temperature over 30 to 60 minutes in such amount that the water content in the ethanol/water mixture is from 65 to 85 volume percent,
- e) continuing shaking/stirring for 1 to 2 hours at the decreased temperature, and
- f) isolating the precipitate and drying the solid residue.

42 (previously presented). The process according to claim 39, which comprises storing the mixture between steps (d) and (e).

43 (previously presented). A process for the manufacture of (+)- or (-)-*erythro*-mefloquine hydrochloride in a crystalline form which exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}), of:

2877 (m), 1601 (s), 1585 (s), 1363 (vs), 1028.2 (w), 320 (m) and 118 (vs),

wherein said process comprises the steps of:

- a) treating with or without vacuum a methyl ethyl ketone solvate of (+)- or (-)-*erythro*-mefloquine hydrochloride at a temperature from 20°C to 100°C, preferably 30°C to 70°C, to remove the methyl ethyl ketone, or
- b) suspending a methyl ethyl ketone solvate of (+)- or (-)-*erythro*-mefloquine hydrochloride in a non-solvent, stirring for a time sufficient to remove methyl ethyl ketone from the solvate, and isolating and then drying the crystals.

44 (previously presented). A process for the manufacture of (+)- or (-)-*erythro*-mefloquine hydrochloride comprising the steps of:

- a) dissolving (+)- or (-)-*erythro*-mefloquine hydrochloride in acetone, tetrahydrofuran or methyl ethyl ketone at a temperature from 40 to 80°C to form a concentrated, saturated or super-saturated solution, cooling and stirring the cooled suspension for a time period sufficient to form the solvate, and isolating and drying the crystals, or

J:\GJE\7647\PTO2-Prelamend.doc\la

11

Docket No. GJE-7647
Serial No. 10/575,998

b) suspending (+)- or (-)-*erythro*-mefloquine hydrochloride in acetone or tetrahydrofuran, stirring the suspension at a temperature from 20 to 35°C for a time sufficient to form the solvate, and isolating and drying the crystals,

and wherein the (+)- or (-)-*erythro*-mefloquine hydrochloride has one or more of the following characteristics:

i) as an acetone solvate, is in the form of a crystalline pseudo-polymorph which exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}) of:

1602 (s), 1585 (s), 1363 (vs), 322 (m) and 118 (vs);

ii) as a tetrahydrofuran solvate, is in the form of a crystalline pseudo-polymorph which exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}), of:

1601 (s), 1585 (s), 1363 (vs), 323 (m) and 119 (vs); and

iii) as a methyl ethyl ketone solvate, exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}), of:

1600 (s), 1585 (s), 1363 (vs), 319 (m) and 118 (vs).

45 (currently amended). A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a (+)- or ~~(-)-*erythro*-mefloquine~~ (-)-*erythro*-mefloquine hydrochloride having one or more of the following characteristics:

a) (+)- or ~~(-)-*erythro*-mefloquine~~ (-)-*erythro*-mefloquine hydrochloride in a crystalline form which exhibits a characteristic X-ray powder diffraction pattern with peaks expressed in d-values (Å) of: 5.95 (s) and 4.02 (w);

b) (+)- or ~~(-)-*erythro*-Mefloquine~~ (-)-*erythro*-mefloquine hydrochloride comprising particles having a size distribution of 30 to 150 μm , in a crystalline form which exhibits a characteristic X-ray powder diffraction pattern with peaks expressed in d-values (Å) of:

22.3 (vw), 11.2 (vs), 9.0 (w), 8.2 (vw), 7.4 (vw), 6.8 (vw), 6.5 (vw), 6.3 (vw), 6.1 (vw), 6.0 (vw), 5.94 (vw), 5.61 (m), 5.42 (w), 4.89 (vw), 4.74 (w), 4.54 (w), 4.12 (s), 4.02 (w), 3.81 (vvs), 3.74 (vs), 3.70 (vw), 3.64 (w), 3.55 (w), 3.47, (vw), 3.40 (vw), 3.34 (vw), 3.31 (vw), 3.26 (vs), 3.11 (vw), 3.04 (w), 2.97 (vw), 2.94 (vw), 2.81 (vw), 2.75 (m), 2.71 (w), 2.69 (w), 2.64 (w), 2.62 (w),

J:\GJE\7647\PTO2-Prelamend.doc\la

12

Docket No. GJE-7647
Serial No. 10/575,998

2.54 (vw), 2.46 (vw), 2.43 (vw), 2.40 (vw), 2.35 (vw), 2.30 (vw), 2.27 (vw), 2.24 (vw), 2.22 (vw), 2.17 (vs), 2.08 (vw), 2.06 (vw), 2.04 (vw), 1.94 (w), 1.91 (vw) and 1.88 (vw);

c) (+)- or (-)-*erythro*-mefloquine hydrochloride comprising particles having a size distribution of 1 to 10 μm , in a crystalline form which exhibits a characteristic X-ray powder diffraction pattern with peaks expressed in d-values (\AA) of:

11.2 (m), 9.0 (w), 8.30 (vw), 7.4 (vw), 6.8 (vw), 6.3 (w), 6.1 (vw), 6.0 (vw), 5.95 (vw), 5.59 (w), 5.42 (w), 4.91 (vw), 4.74 (w), 4.55 (vw), 4.16 (w), 4.12 (s), 4.03 (w), 3.82 (vvs), 3.75 (w), 3.71 (w), 3.64 (w), 3.55 (w), 3.47 (vw), 3.40 (vw), 3.33 (w), 3.26 (w), 3.11 (vw), 3.04 (vw), 2.94 (vw), 2.75 (w), 2.71 (vw), 2.69 (vw), 2.64 (w), 2.62 (vw), 2.54 (vw), 2.46 (vw), 2.43 (vw), 2.40 (vw), 2.35 (vw), 2.30 (vw), 2.26 (vw), 2.22 (vw), 2.17 (w), 2.08 (vw), 2.06 (vw), 1.99 (vw), 1.91 (vw) and 1.89 (vw);

d) (+)- or (-)-*erythro*-mefloquine hydrochloride in a crystalline form which exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}), of:
1030.2 (w) and 85.4 (vs);

e) (+)- or (-)-*erythro*-mefloquine hydrochloride in a crystalline form which exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}), of:
2877 (m), 1601 (s), 1585 (s), 1363 (vs), 1028.2 (w), 320 (m) and 118 (vs);

f) (+)- or (-)-*erythro*-mefloquine hydrochloride which, as an acetone solvate, is in the form of a crystalline pseudo-polymorph which exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}) of:

1602 (s), 1585 (s), 1363 (vs), 322 (m) and 118 (vs);

g) (+)- or (-)-*erythro*-mefloquine hydrochloride which, as a tetrahydrofuran solvate, is in the form of a crystalline pseudo-polymorph which exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}), of:

1601 (s), 1585 (s), 1363 (vs), 323 (m) and 119 (vs);

h) (+)- or (-)-*erythro*-mefloquine hydrochloride which, as a methyl ethyl ketone solvate, exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}), of:

1600 (s), 1585 (s), 1363 (vs), 319 (m) and 118 (vs); and

i) (+)- or (-)-*erythro*-mefloquine hydrochloride, which is substantially in the form of thick columns, cuboids, cubes or cube-like particles.

46 (currently amended). The pharmaceutical composition, according to claim 45, comprising a (+)- or ~~(-)-*erythro*-mefloquine~~ (-)-*erythro*-mefloquine hydrochloride having one or more of the following characteristics:

a) (+)- or ~~(-)-*erythro*-mefloquine~~ (-)-*erythro*-mefloquine hydrochloride in a crystalline form which exhibits a characteristic X-ray powder diffraction pattern with peaks expressed in d-values (Å) of: 5.95 (s) and 4.02 (w);

b) (+)- or (-)-*erythro*-mefloquine hydrochloride comprising particles having a size distribution of 30 to 150 µm, in a crystalline form which exhibits a characteristic X-ray powder diffraction pattern with peaks expressed in d-values (Å) of:

22.3 (vw), 11.2 (vs), 9.0 (w), 8.2 (vw), 7.4 (vw), 6.8 (vw), 6.5 (vw), 6.3 (vw), 6.1 (vw), 6.0 (vw), 5.94 (vw), 5.61 (m), 5.42 (w), 4.89 (vw), 4.74 (w), 4.54 (w), 4.12 (s), 4.02 (w), 3.81 (vvs), 3.74 (vs), 3.70 (vw), 3.64 (w), 3.55 (w), 3.47, (vw), 3.40 (vw), 3.34 (vw), 3.31 (vw), 3.26 (vs), 3.11 (vw), 3.04 (w), 2.97 (vw), 2.94 (vw), 2.81 (vw), 2.75 (m), 2.71 (w), 2.69 (w), 2.64 (w), 2.62 (w), 2.54 (vw), 2.46 (vw), 2.43 (vw), 2.40 (vw), 2.35 (vw), 2.30 (vw), 2.27 (vw), 2.24 (vw), 2.22 (vw), 2.17 (vs), 2.08 (vw), 2.06 (vw), 2.04 (vw), 1.94 (w), 1.91 (vw) and 1.88 (vw);

c) (+)- or (-)-*erythro*-mefloquine hydrochloride comprising particles having a size distribution of 1 to 10 µm, in a crystalline form which exhibits a characteristic X-ray powder diffraction pattern with peaks expressed in d-values (Å) of:

11.2 (m), 9.0 (w), 8.30 (vw), 7.4 (vw), 6.8 (vw), 6.3 (w), 6.1 (vw), 6.0 (vw), 5.95 (vw), 5.59 (w), 5.42 (w), 4.91 (vw), 4.74 (w), 4.55 (vw), 4.16 (w), 4.12 (s), 4.03 (w), 3.82 (vvs), 3.75 (w), 3.71 (w), 3.64 (w), 3.55 (w), 3.47 (vw), 3.40 (vw), 3.33 (w), 3.26 (w), 3.11 (vw), 3.04 (vw), 2.94 (vw), 2.75 (w), 2.71 (vw), 2.69 (vw), 2.64 (w), 2.62 (vw), 2.54 (vw), 2.46 (vw), 2.43 (vw), 2.40 (vw), 2.35 (vw), 2.30 (vw), 2.26 (vw), 2.22 (vw), 2.17 (w), 2.08 (vw), 2.06 (vw), 1.99 (vw), 1.91 (vw) and 1.89 (vw); and

d) (+)- or (-)-*erythro*-mefloquine hydrochloride in a crystalline form which exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}), of:
1030.2 (w) and 85.4 (vs).

47 (currently amended). A method for the treatment of malaria, a movement or neurodegenerative disorder, or an inflammatory or autoimmune disease wherein said method comprises administering, to a patient in need of such treatment, a (+)- or (-)-*erythro*-mefloquine (-)-*erythro*-mefloquine hydrochloride having one or more of the following characteristics:

a) (+)- or ~~(-)-*erythro*-mefloquine~~ (-)-*erythro*-mefloquine hydrochloride in a crystalline form which exhibits a characteristic X-ray powder diffraction pattern with peaks expressed in d-values (\AA) of: 5.95 (s) and 4.02 (w);

b) (+)- or ~~(-)-*erythro*-Mefloquine~~ (-)-*erythro*-mefloquine hydrochloride comprising particles having a size distribution of 30 to 150 μm , in a crystalline form which exhibits a characteristic X-ray powder diffraction pattern with peaks expressed in d-values (\AA) of:
22.3 (vw), 11.2 (vs), 9.0 (w), 8.2 (vw), 7.4 (vw), 6.8 (vw), 6.5 (vw), 6.3 (vw), 6.1 (vw), 6.0 (vw), 5.94 (vw), 5.61 (m), 5.42 (w), 4.89 (vw), 4.74 (w), 4.54 (w), 4.12 (s), 4.02 (w), 3.81 (vvs), 3.74 (vs), 3.70 (vw), 3.64 (w), 3.55 (w), 3.47, (vw), 3.40 (vw), 3.34 (vw), 3.31 (vw), 3.26 (vs), 3.11 (vw), 3.04 (w), 2.97 (vw), 2.94 (vw), 2.81 (vw), 2.75 (m), 2.71 (w), 2.69 (w), 2.64 (w), 2.62 (w), 2.54 (vw), 2.46 (vw), 2.43 (vw), 2.40 (vw), 2.35 (vw), 2.30 (vw), 2.27 (vw), 2.24 (vw), 2.22 (vw), 2.17 (vs), 2.08 (vw), 2.06 (vw), 2.04 (vw), 1.94 (w), 1.91 (vw) and 1.88 (vw);

c) (+)- or (-)-*erythro*-mefloquine hydrochloride comprising particles having a size distribution of 1 to 10 μm , in a crystalline form which exhibits a characteristic X-ray powder diffraction pattern with peaks expressed in d-values (\AA) of:
11.2 (m), 9.0 (w), 8.30 (vw), 7.4 (vw), 6.8 (vw), 6.3 (w), 6.1 (vw), 6.0 (vw), 5.95 (vw), 5.59 (w), 5.42 (w), 4.91 (vw), 4.74 (w), 4.55 (vw), 4.16 (w), 4.12 (s), 4.03 (w), 3.82 (vvs), 3.75 (w), 3.71 (w), 3.64 (w), 3.55 (w), 3.47 (vw), 3.40 (vw), 3.33 (w), 3.26 (w), 3.11 (vw), 3.04 (vw), 2.94 (vw), 2.75 (w), 2.71 (vw), 2.69 (vw), 2.64 (w), 2.62 (vw), 2.54 (vw), 2.46 (vw), 2.43 (vw), 2.40

(vw), 2.35 (vw), 2.30 (vw), 2.26 (vw), 2.22 (vw), 2.17 (w), 2.08 (vw), 2.06 (vw), 1.99 (vw), 1.91 (vw) and 1.89 (vw);

d) (+)- or (-)-*erythro*-mefloquine hydrochloride in a crystalline form which exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}), of:

1030.2 (w) and 85.4 (vs);

e) (+)- or (-)-*erythro*-mefloquine hydrochloride in a crystalline form which exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}), of:

2877 (m), 1601 (s), 1585 (s), 1363 (vs), 1028.2 (w), 320 (m) and 118 (vs);

f) (+)- or (-)-*erythro*-mefloquine hydrochloride which, as an acetone solvate, is in the form of a crystalline pseudo-polymorph which exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}) of:

1602 (s), 1585 (s), 1363 (vs), 322 (m) and 118 (vs);

g) (+)- or (-)-*erythro*-mefloquine hydrochloride which, as a tetrahydrofuran solvate, is in the form of a crystalline pseudo-polymorph which exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}), of:

1601 (s), 1585 (s), 1363 (vs), 323 (m) and 119 (vs);

h) (+)- or (-)-*erythro*-mefloquine hydrochloride which, as a methyl ethyl ketone solvate, exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}), of:

1600 (s), 1585 (s), 1363 (vs), 319 (m) and 118 (vs); and

i) (+)- or (-)-*erythro*-mefloquine hydrochloride, which is substantially in the form of thick columns, cuboids, cubes or cube-like particles.

48 (currently amended). The method, according to claim 47, which comprises administering a (+)- or (-)-~~*erythro*-mefloquine~~ (-)-*erythro*-mefloquine hydrochloride having one or more of the following characteristics:

a) (+)- or (-)-~~*erythro*-mefloquine~~ (-)-*erythro*-mefloquine hydrochloride in a crystalline form which exhibits a characteristic X-ray powder diffraction pattern with peaks expressed in d-values (\AA) of: 5.95 (s) and 4.02 (w);

16

Docket No. GJE-7647
Serial No. 10/575,998

b) (+)- or (-)-*erythro*-mefloquine hydrochloride comprising particles having a size distribution of 30 to 150 μm , in a crystalline form which exhibits a X-ray powder diffraction pattern with peaks expressed in d-values (\AA) of:

22.3 (vw), 11.2 (vs), 9.0 (w), 8.2 (vw), 7.4 (vw), 6.8 (vw), 6.5 (vw), 6.3 (vw), 6.1 (vw), 6.0 (vw), 5.94 (vw), 5.61 (m), 5.42 (w), 4.89 (vw), 4.74 (w), 4.54 (w), 4.12 (s), 4.02 (w), 3.81 (vvs), 3.74 (vs), 3.70 (vw), 3.64 (w), 3.55 (w), 3.47, (vw), 3.40 (vw), 3.34 (vw), 3.31 (vw), 3.26 (vs), 3.11 (vw), 3.04 (w), 2.97 (vw), 2.94 (vw), 2.81 (vw), 2.75 (m), 2.71 (w), 2.69 (w), 2.64 (w), 2.62 (w), 2.54 (vw), 2.46 (vw), 2.43 (vw), 2.40 (vw), 2.35 (vw), 2.30 (vw), 2.27 (vw), 2.24 (vw), 2.22 (vw), 2.17 (vs), 2.08 (vw), 2.06 (vw), 2.04 (vw), 1.94 (w), 1.91 (vw) and 1.88 (vw);

c) (+)- or (-)-*erythro*-mefloquine hydrochloride comprising particles having a size distribution of 1 to 10 μm , in a crystalline form which exhibits a characteristic X-ray powder diffraction pattern with peaks expressed in d-values (\AA) of:

11.2 (m), 9.0 (w), 8.30 (vw), 7.4 (vw), 6.8 (vw), 6.3 (w), 6.1 (vw), 6.0 (vw), 5.95 (vw), 5.59 (w), 5.42 (w), 4.91 (vw), 4.74 (w), 4.55 (vw), 4.16 (w), 4.12 (s), 4.03 (w), 3.82 (vvs), 3.75 (w), 3.71 (w), 3.64 (w), 3.55 (w), 3.47 (vw), 3.40 (vw), 3.33 (w), 3.26 (w), 3.11 (vw), 3.04 (vw), 2.94 (vw), 2.75 (w), 2.71 (vw), 2.69 (vw), 2.64 (w), 2.62 (vw), 2.54 (vw), 2.46 (vw), 2.43 (vw), 2.40 (vw), 2.35 (vw), 2.30 (vw), 2.26 (vw), 2.22 (vw), 2.17 (w), 2.08 (vw), 2.06 (vw), 1.99 (vw), 1.91 (vw) and 1.89 (vw); and

d) (+)- or (-)-*erythro*-mefloquine hydrochloride in a crystalline form which exhibits characteristic Raman bands, expressed in wave numbers (cm^{-1}), of:

1030.2 (w) and 85.4 (vs).